title: Clinical implications of PROGRESS: questions and answers.
authors.affiliation: Institute for International Health, University of Sydney, Newtown, NSW, Australia. chalmers@iih.usyd.edu.au
authors.forename: John
authors.initials: J
authors.lastname: Chalmers
authors.forename: Harold P
authors.initials: HP
authors.lastname: Adams
authors.forename: Geoffrey A
authors.initials: GA
authors.lastname: Donnan
authors.forename: Kim
authors.initials: K
authors.lastname: Fox
authors.forename: Stephen
authors.initials: S
authors.lastname: MacMahon
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mancia
authors.forename: Christophe
authors.initials: C
authors.lastname: Tzourio
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D020913:Perindopril / Q000627:therapeutic use*; D055502:Secondary Prevention; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D020913:Perindopril